Aerie Pharma (AERI) Misses Q2 EPS by 25c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. SPY
5. ANT
6. META
7. BA
8. INTC
9. JBLU
10. AAPL

Go back to Aerie Pharma (AERI) Misses Q2 EPS by 25c

Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update

August 6, 2020 4:01 PM EDT

Year-to-Date Net Revenues of $38.4 Million Increased 44% over 2019

Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustained Release

AR-15512 Trial for Dry Eye, COMET-1, Set to Initiate this Year

Conference Call and Webcast Today, August 6th, at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular... More